Drug intelligence / Profile preview

OR-812

Development stage: Preclinical
Lead developer: Orphagen Pharmaceuticals
Modality: Small Molecules

Overview

OR-812 is a small molecule drug developed by Orphagen Pharmaceuticals. It acts as an antagonist of the retinoic acid receptor alpha (RARα). The primary therapeutic areas under investigation for OR-812 are digestive system disorders, specifically inflammatory bowel diseases, and contraception. As of the latest available information, preliminary safety studies indicate a robust safety margin for this compound. The drug is currently in preclinical development.

Targets

RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on OR-812.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OR-812.

Explore the full profile